Evidence map›Paper›PMID 30697252›Full record

ReviewArchives of medical science : AMS2019

Efficacy and safety of various anti-rheumatic treatments for patients with rheumatoid arthritis: a network meta-analysis.

Kexun Ma, Ling Li, Chunhui Liu, Lingling Zhou, Xueping Zhou

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Archives of medical science : AMS, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Gait disturbances in patients with rheumatoid arthritis.Archives of medical science : AMS · 2024
    Article
  6. Article
  7. Article
  8. Review
  9. Static Foot Disturbances and the Quality of Life of Older Person with Rheumatoid Arthritis.International journal of environmental research and public health · 2022
    Article
  10. Article
  11. Acute liver failure secondary to toxic exposure in children.Archives of medical science : AMS · 2022
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Kexun MaThe First Clinical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Ling LiDepartment of Rheumatology, Taizhou Hospital of TCM, Taizhou, Jiangsu, China.
Chunhui LiuThe First Clinical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Lingling ZhouCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Xueping ZhouThe First Clinical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Nanjing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBiologics and traditional disease-modifying anti-rheumatic drugs (DMARDs) are generally used in treating patients with rheumatoid arthritis (RA). Previous studies have presented abundant data and information about the efficacy of such treatments, but the results were incomplete and inconclusive. This network meta-analysis was conducted to compare and assess the efficacy and safety of 15 therapies employing biologics and DMARDs for RA patients. MATERIAL AND

methodsSix outcomes (American College of Rheumatology 20% response rate (ACR20), ACR50, ACR70, remission, adverse events (AEs) and serious adverse events (SAEs)) were used to evaluate the efficacy and safety of different treatments. The node-splitting method was used to assess the inconsistency, and the rank probabilities of the therapies were estimated by surface under the cumulative ranking curve. Besides, Jadad scale was used to evaluate the methodological quality of eligible studies.

resultsA total of 67 randomized controlled trials with 20,898 patients met the inclusion criteria. Most of the therapies presented better performance than conventional DMARDs (cDMARDs) and placebo in ACR20, ACR50 and ACR70. Conversely, the safety of cDMARDs and placebo seemed to be superior in AEs and SAEs. Also, tocilizumab (TCZ) and TCZ + methotrexate (MTX) showed better remission in pain compared to other treatments. Overall, certolizumab pegol (CZP) + MTX and TCZ + MTX had higher probability than the other treatments in efficacy outcomes.

conclusionsWe recommend CZP + MTX as the optimal drug therapy because it has the highest ranking in efficacy outcomes and relatively low risk of adverse events. TCZ + MTX is recommended as an alternative. Abatacept (ABT) and cDMARDs are not recommended due to their low efficacy.

Indexed as

biologicsdisease-modifying anti-rheumatic drugsnetwork meta-analysisrheumatoid arthritis

Identifiers

PMID30697252
PMCPMC6348345
OpenAlexW2911328830

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.